Chandra Bhagat Pharma Ltd
NSE: BSE: 542934
₹34.76
(-4.98%)
Wed, 11 Mar 2026, 02:15 pm
Market Cap0
PE Ratio0
Dividend0
Distribution Services
Medical Distributors
24.5KChandra Bhagat Pharma Analysis
dividend
- Unable to evaluate Chandra Bhagat Pharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Chandra Bhagat Pharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
health
- Chandra Bhagat Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Chandra Bhagat Pharma is profitable, therefore cash runway is not a concern.
- Chandra Bhagat Pharma is profitable, therefore cash runway is not a concern.
- Debt is covered by short term assets, assets are 2.6x debt.
- Chandra Bhagat Pharma's cash and other short term assets cover its long term commitments.
- Debt is not well covered by operating cash flow (12.2%, less than 20% of total debt).
- Interest payments on debt are not well covered by earnings (EBIT is 1.4x annual interest expense, ideally 3x coverage).
- Chandra Bhagat Pharma's level of debt (217.5%) compared to net worth is high (greater than 40%).
- High level of physical assets or inventory.
management
- The average tenure for the Chandra Bhagat Pharma board of directors is less than 3 years, this suggests a new board.
- The average tenure for the Chandra Bhagat Pharma management team is less than 2 years, this suggests a new team.
misc
- Chandra Bhagat Pharma is not covered by any analysts.
- Chandra Bhagat Pharma has significant price volatility in the past 3 months.
past
- Chandra Bhagat Pharma's 1-year earnings growth is negative, it can't be compared to the 5-year average.
- Chandra Bhagat Pharma used its assets less efficiently than the IN Healthcare industry average last year based on Return on Assets.
- Chandra Bhagat Pharma has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- Chandra Bhagat Pharma's 1-year earnings growth is negative, it can't be compared to the IN Healthcare industry average.
value
- Chandra Bhagat Pharma's share price is below the future cash flow value, and at a moderate discount (> 20%).
- Chandra Bhagat Pharma's share price is below the future cash flow value, and at a substantial discount (> 40%).
- Chandra Bhagat Pharma is good value based on assets compared to the IN Healthcare industry average.
- Chandra Bhagat Pharma is overvalued based on earnings compared to the IN Healthcare industry average.
- Chandra Bhagat Pharma is overvalued based on earnings compared to the India market.
- BSE:542934 is down -13.4% underperforming the Healthcare industry which returned 5.4% over the past month.
- BSE:542934 is down -13.4% underperforming the market in India which returned 8% over the past month.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800